News - OBI Pharma 台灣浩鼎

2024.Aug.22

Corporate

The 2nd World ADC Linker & Conjugation Summit – OBI Pharma Presents Results on Patented Enzyme - EndoSymeOBI® - for ADCs

2024.Aug.07

Corporate

OBI-992 has been approved by US FDA for Orphan Drug Designation for the treatment of gastric cancer

2024.Jul.30

Corporate

OBI Pharma: An Exciting Launching Pad for Young Scientists

2024.Jul.29

Corporate

OBI’s Proprietary ADC Platform GlycOBI® Seeks Collaborative Partnerships for Development

2024.Jul.26

Corporate

Vision: OBI Presents a Five-Year Strategic Plan

2024.Jul.25

Corporate

OBI Shares Opportunities and Challenges of ADC Development at BioAsia2024

2024.Jul.09

Corporate

OBI 's ADC Technology Platform GlycOBI® and Enzyme EndoSymeOBI® Two Trademarks Approved by Taiwan Intellectual Property Office

2024.Jun.28

Corporate

OBI Pharma shareholders’ meeting launches new company strategy and embraces transformation

2024.Jun.26

Media

OBI 's Proprietary Enzyme EndoSymeOBI™ Featured on Cover of Prestigious International Journal, JACS Au.

2024.Jun.21

Award & Certification

Dr. Heidi Wang, CEO of OBI Pharma, Inc., Selected as One of the Top 10 Managers of High-performing Enterprises by the Golden Torch Award

Announcements

Latest announcements

Events

Latest events